SciSparc to expand mid-stage trial of Tourette Syndrome treatment to U.S. clinical site

• Israel-based SciSparc (NASDAQ:SPRC) on Friday said it had started the process of preparing for an investigational new drug application for its phase 2b trial evaluating its SCI-110 drug candidate for Tourette Syndrome.
• As part of the process, the company will expand the mid-stage trial to include a U.S. clinical site.
• SciSparc is a cannabinoid pharmaceuticals company. It is developing SCI-110, which contains a synthetic form of THC, for the treatment of nervous system disorder Tourette Syndrome, which is characterized by chronic motor and vocal tics.
• The company recently got ethics committee approvals from Germany and Israel for the first two sites of the trial.
• SPRC stock -3.5% to $2.22 in premarket trading.